{
  "docId": "019de073-8606-762c-9e2e-06d280bc8199",
  "docSlug": "fe3546a131d6b03dbc05b580d2cda1c4",
  "documentTitle": "CTI BioPharma | Investor Presentation Deck | 24 slides",
  "authorId": "cti-biopharma",
  "authorName": "CTI BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 24,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes market sizing data and clinical characteristics of the target patient segment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8606-762c-9e2e-06d280bc8199/4",
  "deckHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199",
  "deckJsonHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199.json",
  "deckAnchorHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.78
      },
      "kind": "callout",
      "text": "VONJO is the only agent specifically studied in cytopenic MF",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab69527a-1ca1-4ce5-9057-39338f3aebcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.42,
        "x": 0.06,
        "y": 0.16
      },
      "kind": "callout",
      "text": "~$3B Potential MF Market by 2026",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea097930-403f-4e4e-80fe-ad6b85c71f33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.55,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Anemia",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2016ab0-a6c2-4d94-a6ae-8f827b4c0e2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Platelet Count",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35cbdcd0-bed4-4536-8ec3-8a8e43fcdc30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.88,
        "x": 0.06,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "1. Evaluate Pharma... 6. In a randomised Phase 3 trial. VONJO is indicated for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis with a baseline platelet count of <50 x 10^9/L.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a90305b7-d4ea-4720-a32c-e2cbf8101d46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "list",
      "text": "Up to 2/3rd of the 21,000 MF population is cytopenic; ~14K patients have platelet count <100 x 10^9/L; ~7K patients have platelet count <50 x 10^9/L",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0802b118-668f-4321-891d-73de436db3a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.06,
        "y": 0.43
      },
      "kind": "list",
      "text": "Other cytopenic MF characteristics: Hemoglobin <10 g/dL, RBC transfusions requirement, Enlarged spleen, Constitutional symptoms",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74e75ca0-824c-4e13-a6b3-3eeaa9a44e82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Cytopenic Patients are the Largest Segment of MF",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a081dd3a-9faf-4ab0-83db-ee6b78442345",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "9d4d57fd-2c4b-4bd3-bcf0-3e7a5b8cf185",
      "evidence": "Segments MF population by cytopenic status and platelet count",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}